Sanofi-Aventis and DNDi sign agreement on trypanosomiasis drug
This article was originally published in Scrip
Executive Summary
A potential new compound to treat the parasitic disease African trypanosomiasis is set to enter clinical development, following an agreement between the Drugs for Neglected Diseases initiative (DNDi) and Sanofi-Aventis.